HC Wainwright & Co. Reiterates Buy on Can Fite Biofarma, Maintains $18 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Vernon Bernardino has reiterated a Buy rating on Can Fite Biofarma (AMEX:CANF), maintaining an $18 price target. This reaffirmation highlights the firm's continued confidence in the company's prospects.
May 09, 2024 | 5:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reiterates a Buy rating on Can Fite Biofarma, with an $18 price target, indicating strong confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of an $18 price target by a reputable analyst firm like HC Wainwright & Co. suggests a strong belief in Can Fite Biofarma's potential for growth. This endorsement could positively influence investor sentiment and potentially lead to an uptick in CANF's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100